Emergent BioSolutions | EBS - Cost Of Sales


Emergent BioSolutions reported $381.2M in Cost of Sales for its fiscal quarter ending in June of 2023.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 26.22M 4.58M Dec/2025
Akebia Therapeutics USD 10.34M 441K Dec/2025
ALKERMES USD 46.21M 5.38M Dec/2025
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
Amarin USD 26.05M 1.41M Dec/2025
ANI Pharmaceuticals USD 122.88M 6.86M Dec/2025
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Coherus Biosciences USD 4.04M 324K Dec/2025
Emergent BioSolutions USD 381.2M 226.1M Jun/2023
Exelixis USD 26.48M 7.91M Dec/2025
Glaxosmithkline GBP 3.47B 461.37M Dec/2025
Heron Therapeutics USD 11.12M 795K Dec/2025
Ionis Pharmaceuticals USD 8M 5.66M Dec/2025
Ironwood Pharmaceuticals USD 29.83M 560K Sep/2024
Lexicon Pharmaceuticals USD 201K 191K Dec/2025
Lonza CHF 2.28B 189M Jun/2025
Merck USD 3.32B 531M Dec/2025
Moderna USD 452M 245M Dec/2025
Myriad Genetics USD 63M 1.1M Dec/2025
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
Pacira USD 54.62M 6.02M Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
PTC Therapeutics USD 16.3M 7.02M Dec/2025
Sanofi EUR 3.67B 621M Mar/2026
Sarepta Therapeutics USD 399.38M 247.93M Dec/2025
United Therapeutics USD 474.7M 373.8M Dec/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Xoma 116K 112.7K Jun/2024